Skip to content

By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Discover updates to RELiZORB and what they may mean for you #


If you require tube feeding, formula alone may not be enough to give you the nutrients you need. RELiZORB works with your tube-feeding formula to help you get the most out of every feed

What could better fat absorption from your tube-feeding formula mean for you?


  • Designed to break down fats and improve absorption
  • Compatible with a wide range of enteral formulas*
  • Equipped for use with continuous and bolus setups
RELiZORB (immobilized lipase) feeding tube

Connect. Hydrolyze. Absorb.

The inability to break down fats from enteral formula can cause fat malabsorption. Fats absorbed from nutrition are important for proper health. If you have fat malabsorption and need help hydrolyzing (breaking down) fats from enteral tube-feeding formula, your doctor may prescribe RELiZORB.

RELiZORB is a digestive enzyme cartridge that contains iLipase®, which is the enzyme lipase attached to small white beads. RELiZORB connects directly to your feeding tube, and as the formula passes through, it makes contact with the iLipase, hydrolyzing (or breaking down) the fat in formula into absorbable forms (called fatty acids and monoglycerides)—all before entering your body.


The digestive enzyme lipase is attached to small white beads stored within the RELiZORB cartridge, which connects directly to your feeding tube. The iLipase remains in the cartridge and is not ingested.

RELiZORB (immobilized lipase) cartridge

See how RELiZORB works

RELiZORB is indicated for pediatric patients as young as 2 years and adult patients

See how RELiZORB is helping a 17-year-old student and lacrosse player living with cystic fibrosis

*Please see list of compatible formulas and hydrolysis information.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

  • RELiZORB is for use with enteral feeding only.

RELiZORB is indicated for use in pediatric patients (ages 2 years and above) and adult patients to hydrolyze fats in enteral formula.

  • RELiZORB is for use with enteral feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral formula or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, enteral formula leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral formulas compatible with RELiZORB can be found at
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for bolus syringe push. A detailed listing of formulas, pumps, and enteral feeding supplies compatible with RELiZORB can be found at
  • Do not use excessive force when using RELiZORB with enteral syringe push feeding methods.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding.
  • Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.